95 related articles for article (PubMed ID: 26872286)
1. Pharmacotherapy follow-up of key points in the safety of oral antineoplastic agents.
Escudero-Vilaplana V; Ribed A; Romero-Jimenez RM; Herranz-Alonso A; Sanjurjo-Saez M
Eur J Cancer Care (Engl); 2017 May; 26(3):. PubMed ID: 26872286
[TBL] [Abstract][Full Text] [Related]
2. Pharmaceutical care program for onco-hematologic outpatients: safety, efficiency and patient satisfaction.
Ribed A; Romero-Jiménez RM; Escudero-Vilaplana V; Iglesias-Peinado I; Herranz-Alonso A; Codina C; Sanjurjo-Sáez M
Int J Clin Pharm; 2016 Apr; 38(2):280-8. PubMed ID: 26715547
[TBL] [Abstract][Full Text] [Related]
3. Novel mobile application for direct communication between pharmacists and patients treated with oral antineoplastic agents.
Collado-Borrell R; Escudero-Vilaplana V; Ribed A; Jiménez RR; Peinado II; Herranz-Alonso A; Sanjurjo-Sáez M
Am J Health Syst Pharm; 2020 Aug; 77(17):1393-1402. PubMed ID: 32620958
[TBL] [Abstract][Full Text] [Related]
4. A smartphone app to improve the safety of patients undergoing treatment with oral antineoplastic agents: 4 years of experience in a university hospital.
Villanueva-Bueno C; Collado-Borrell R; Escudero-Vilaplana V; Revuelta-Herrero JL; Marzal-Alfaro MB; González-Haba E; Arranz-Arija JÁ; Osorio S; Herranz-Alonso A; Sanjurjo-Saez M
Front Public Health; 2022; 10():978783. PubMed ID: 36407983
[TBL] [Abstract][Full Text] [Related]
5. Guiding pharmacist clinical interviews: a safety tool to support the education of patients treated with oral antineoplastic agents.
Ribed A; Escudero-Vilaplana V; Romero-Jimenez RM; Iglesias-Peinado I; Herranz-Alonso A; Sanjurjo-Saez M
Expert Opin Drug Saf; 2016; 15(4):427-35. PubMed ID: 26854363
[TBL] [Abstract][Full Text] [Related]
6. Role of clinical pharmacists to prevent drug interactions in cancer outpatients: a single-centre experience.
Lopez-Martin C; Garrido Siles M; Alcaide-Garcia J; Faus Felipe V
Int J Clin Pharm; 2014 Dec; 36(6):1251-9. PubMed ID: 25326824
[TBL] [Abstract][Full Text] [Related]
7. Oral antineoplastic agents: assessment of safety and dose adjustments in clinical practice.
Escudero-Vilaplana V; Revuelta-Herrero JL; Collado-Borrell R; Marzal-Alfaro B; Gimenez-Manzorro A; Herranz-Alonso A; Sanjurjo-Saez M
Expert Opin Drug Saf; 2019 Sep; 18(9):861-868. PubMed ID: 31282227
[No Abstract] [Full Text] [Related]
8. Impact of pharmaceutical care on cardiovascular risk among older HIV patients on antiretroviral therapy.
Domingues EA; Ferrit-Martín M; Calleja-Hernández MÁ
Int J Clin Pharm; 2017 Feb; 39(1):52-60. PubMed ID: 27864732
[TBL] [Abstract][Full Text] [Related]
9. Drug interactions with oral antineoplastic drugs: The role of the pharmacist.
Riu-Viladoms G; Carcelero San Martín E; Martín-Conde MT; Creus N
Eur J Cancer Care (Engl); 2019 Jan; 28(1):e12944. PubMed ID: 30324634
[TBL] [Abstract][Full Text] [Related]
10. Utilization patterns for oral oncology medications in a specialty pharmacy cycle management program.
Deutsch S; Koerner P; Miller RT; Craft Z; Fancher K
J Oncol Pharm Pract; 2016 Feb; 22(1):68-75. PubMed ID: 25301744
[TBL] [Abstract][Full Text] [Related]
11. Computerized pharmaceutical intervention to reduce reconciliation errors at hospital discharge in Spain: an interrupted time-series study.
García-Molina Sáez C; Urbieta Sanz E; Madrigal de Torres M; Vicente Vera T; Pérez Cárceles MD
J Clin Pharm Ther; 2016 Apr; 41(2):203-8. PubMed ID: 26916590
[TBL] [Abstract][Full Text] [Related]
12. Real-life drug-drug and herb-drug interactions in outpatients taking oral anticancer drugs: comparison with databases.
Prely H; Herledan C; Caffin AG; Baudouin A; Larbre V; Maire M; Schwiertz V; Vantard N; Ranchon F; Rioufol C
J Cancer Res Clin Oncol; 2022 Mar; 148(3):707-718. PubMed ID: 33914124
[TBL] [Abstract][Full Text] [Related]
13. Impact of outpatient interventions made at an ambulatory cancer centre oncology pharmacy in Singapore.
Chew C; Chiang J; Yeoh TT
J Oncol Pharm Pract; 2015 Apr; 21(2):93-101. PubMed ID: 24477774
[TBL] [Abstract][Full Text] [Related]
14. EPICC study: evaluation of pharmaceutical intervention in cancer care.
Vantard N; Ranchon F; Schwiertz V; Gourc C; Gauthier N; Guedat MG; He S; Kiouris E; Alloux C; You B; Souquet PJ; Freyer G; Salles G; Trillet-Lenoir V; Rioufol C
J Clin Pharm Ther; 2015 Apr; 40(2):196-203. PubMed ID: 25594148
[TBL] [Abstract][Full Text] [Related]
15. Oral adverse events in cancer patients treated with VEGFR-directed multitargeted tyrosine kinase inhibitors.
Yuan A; Kurtz SL; Barysauskas CM; Pilotte AP; Wagner AJ; Treister NS
Oral Oncol; 2015 Nov; 51(11):1026-1033. PubMed ID: 26403941
[TBL] [Abstract][Full Text] [Related]
16. Clinical and economic impact of pharmacists' intervention in a large volume chemotherapy preparation unit.
Han JM; Ah YM; Suh SY; Jung SH; Hahn HJ; Im SA; Lee JY
Int J Clin Pharm; 2016 Oct; 38(5):1124-32. PubMed ID: 27365091
[TBL] [Abstract][Full Text] [Related]
17. Comparative efficacy of sunitinib versus sorafenib as first-line treatment for patients with metastatic renal cell carcinoma.
Park SJ; Lee JL; Park I; Park K; Ahn Y; Ahn JH; Lee DH; Ahn S; Song C; Hong JH; Kim CS; Ahn H
Chemotherapy; 2012; 58(6):468-74. PubMed ID: 23548259
[TBL] [Abstract][Full Text] [Related]
18. Pharmacists' perceived knowledge of and confidence in dispensing oral antineoplastic agents.
Dayer L; Dunn E; Pace A; Flowers S
J Am Pharm Assoc (2003); 2016; 56(2):141-4.e2. PubMed ID: 27000164
[TBL] [Abstract][Full Text] [Related]
19. Impact of medication reconciliation at discharge on continuity of patient care in France.
Van Hollebeke M; Talavera-Pons S; Mulliez A; Sautou V; Bommelaer G; Abergel A; Boyer A
Int J Clin Pharm; 2016 Oct; 38(5):1149-56. PubMed ID: 27432017
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of clinical pharmacy services in a hematology/oncology outpatient setting.
Shah S; Dowell J; Greene S
Ann Pharmacother; 2006 Sep; 40(9):1527-33. PubMed ID: 16882869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
